TY - JOUR
T1 - Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy
T2 - an ESC EORP registry
AU - European Soc Cardiology Study Grp
AU - Sliwa, Karen
AU - Petrie, Mark C.
AU - van der Meer, Peter
AU - Mebazaa, Alexandre
AU - Hilfiker-Kleiner, Denise
AU - Jackson, Alice M.
AU - Maggioni, Aldo P.
AU - Laroche, Cecile
AU - Regitz-Zagrosek, Vera
AU - Schaufelberger, Maria
AU - Tavazzi, Luigi
AU - Roos-Hesselink, Jolien W.
AU - Seferovic, Petar
AU - van Spaendonck-Zwarts, Karin
AU - Mbakwem, Amam
AU - Boehm, Michael
AU - Mouquet, Frederic
AU - Pieske, Burkert
AU - Johnson, Mark R.
AU - Hamdan, Righab
AU - Ponikowski, Piotr
AU - Van Veldhuisen, Dirk J.
AU - McMurray, John J.
AU - Bauersachs, Johann
PY - 2020/10/14
Y1 - 2020/10/14
N2 - Aims We sought to describe the clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy (PPCM) globally.Methods and results In 2011, >100 national and affiliated member cardiac societies of the European Society of Cardiology (ESC) were contacted to contribute to a global registry on PPCM, under the auspices of the ESC EURObservational Research Programme. These societies were tasked with identifying centres who could participate in this registry. In low-income countries, e.g. Mozambique or Burkina Faso, where there are no national societies due to a shortage of cardiologists, we identified potential participants through abstracts and publications and encouraged participation into the study. Seven hundred and thirty-nine women were enrolled in 49 countries in Europe (33%), Africa (29%), Asia-Pacific (15%), and the Middle East (22%). Mean age was 31 +/- 6 years, mean left ventricular ejection fraction (LVEF) was 31 +/- 10%, and 10% had a previous pregnancy complicated by PPCM. Symptom-onset occurred most often within 1 month of delivery (44%). At diagnosis, 67% of patients had severe (NYHA III/IV) symptoms and 67% had a LVEF 50%) occurred only in 46%, most commonly in Asia-Pacific (62%), and least commonly in the Middle East (25%). Neonatal death occurred in 5% with marked regional variation (Europe 2%, the Middle East 9%).Conclusion Peripartum cardiomyopathy is a global disease, but clinical presentation and outcomes vary by region. Just under half of women experience myocardial recovery. Peripartum cardiomyopathy is a disease with substantial maternal and neonatal morbidity and mortality.
AB - Aims We sought to describe the clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy (PPCM) globally.Methods and results In 2011, >100 national and affiliated member cardiac societies of the European Society of Cardiology (ESC) were contacted to contribute to a global registry on PPCM, under the auspices of the ESC EURObservational Research Programme. These societies were tasked with identifying centres who could participate in this registry. In low-income countries, e.g. Mozambique or Burkina Faso, where there are no national societies due to a shortage of cardiologists, we identified potential participants through abstracts and publications and encouraged participation into the study. Seven hundred and thirty-nine women were enrolled in 49 countries in Europe (33%), Africa (29%), Asia-Pacific (15%), and the Middle East (22%). Mean age was 31 +/- 6 years, mean left ventricular ejection fraction (LVEF) was 31 +/- 10%, and 10% had a previous pregnancy complicated by PPCM. Symptom-onset occurred most often within 1 month of delivery (44%). At diagnosis, 67% of patients had severe (NYHA III/IV) symptoms and 67% had a LVEF 50%) occurred only in 46%, most commonly in Asia-Pacific (62%), and least commonly in the Middle East (25%). Neonatal death occurred in 5% with marked regional variation (Europe 2%, the Middle East 9%).Conclusion Peripartum cardiomyopathy is a global disease, but clinical presentation and outcomes vary by region. Just under half of women experience myocardial recovery. Peripartum cardiomyopathy is a disease with substantial maternal and neonatal morbidity and mortality.
KW - Peripartum cardiomyopathy
KW - Registry
KW - Outcome
KW - HEART-FAILURE ASSOCIATION
KW - CARDIOLOGY WORKING GROUP
KW - WORLDWIDE REGISTRY
KW - EUROPEAN-SOCIETY
KW - PREDICTORS
U2 - 10.1093/eurheartj/ehaa455
DO - 10.1093/eurheartj/ehaa455
M3 - Article
SN - 0195-668X
VL - 41
SP - 3787
EP - 3797
JO - European Heart Journal
JF - European Heart Journal
IS - 39
ER -